Beyond product cycles: the systems, research and decisions that change how the world works.
The appeals court says software disclosed to a reseller can retain trade-secret protection when access is governed by licences and confidentiality duties. SS&C’s case against Arcesium may proceed, but the ruling does not find that misappropriation occurred.
Read story
The Federal Circuit affirmed that Sonos does not infringe Google’s digital-rights-management patent because grouped speakers do not all directly use the claimed private key. The nonprecedential ruling shows how a few technical words can decide a connected-device patent case before trial.
Read story
Marvell has agreed to acquire Lumentum in an all-stock transaction that would combine custom AI silicon and switching with lasers, transceivers and optical-circuit switching. The scale is extraordinary, but the deal is a proposed 2028 combination—not completed consolidation.
Read story
The Unified Patent Court has held Enanta’s European coronavirus-protease patent invalid and rejected its infringement case against Pfizer’s Paxlovid across 18 participating states. The cross-border result is clear; the legal and technical reasoning is not, because the judgment has not been made public.
Read story
A US appeals court reversed a $9.15 million attorneys’ fee award against ChromaDex and Dartmouth, finding that their defense of nicotinamide-riboside supplement patents was not exceptionally meritless. The decision does not revive the invalid claims, but it draws a consequential line between losing a natural-product patent case and litigating one unreasonably.
Read story
After a record $6.3 billion theft, Binance says it used emergency reserves, an insurance fund and corporate money to replace most affected assets. The remaining tokens are less liquid, withdrawals are still suspended, and the complete cryptographic reserve proof is not due until Tuesday.
Read story
The appeals court reversed an order compelling a patent buyer’s unredacted purchase agreement after Europe’s Unified Patent Court had rejected the same evidence request as premature. The ruling limits, but does not eliminate, U.S. discovery assistance for foreign patent cases.
Read story
The agreement would close a decade-old antitrust fight over insulin-pen patents listed in the FDA’s Orange Book. A court had already called the listings improper and exclusionary, but causation, Sanofi’s defense and damages remained unresolved.
Read story
The Legal Board of Appeal revived an anonymized divisional application filed one day after its parent patent was granted, finding that applicants may rely on the EPO’s published outage safeguards. The decision is narrow, evidence-dependent and not a licence to ignore deadlines.
Read story